Bristol Myers Squibb’s RYZ101 Improves Progression-Free Survival; Admilparant Hits IPF Endpoint at Lower Dose
Bristol Myers’ admilparant hit its IPF goal only at the lower dose. The higher-dose miss raised dose-response questions and sent Contineum shares down 25%.